Clinical trials: Organophosphate Exposure
Cicatrix, Wound-healing
Investigation Into the Safety and Scar-improvement Efficacy of Intradermal Juvidex Dosed Once or Three Times
The purpose of this study was to investigate the scar-improvement efficacy of three doses of intradermal Juvidex given once only or three times in male and female subjects and to collect further safety and tolerability data for…
- Trial name
- NCT00984516
- Testing
- Juvidex
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Renovo
Organophosphate Exposure
An Exploratory Phase 1 Microdose Study of PRX-105
Exploratory phase 1, first in human, open label, non-randomized, single-dose study of PRX-105, administered intravenously by slow bolus injection to 10 healthy volunteers.
- Trial name
- NCT01093859
- Testing
- PRX-105
- Where
- Israel
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Protalix
Ulcerative Colitis
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
The purpose of this study is to evaluate association between ozanimod exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.
- Trial name
- NCT05953402
- Where
- United States
- Volunteers
- 1,182 people
- Sponsor
- Bristol-Myers Squibb
Parkinson's Disease (PD)
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT04379050
- Testing
- ABBV-951
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 130 people
- Sponsor
- AbbVie
Parkinson's Disease (PD)
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT04750226
- Testing
- ABBV-951
- Where
- 52 sites in United States, Australia
- Volunteers
- 118 people
- Sponsor
- AbbVie